Psychemedics Corporation (PMD) |
| 2.67 2.67 (100%) 02-10 16:00 |
| Open: | 2.67 |
| High: | 2.67 |
| Low: | 2.67 |
| Volume: | 112,269 |
| Market Cap: | 16(M) |
| PE Ratio: | -5.24 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Diagnostics & Research |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 9.19 |
| Resistance 1: | 7.87 |
| Pivot price: | 6.94 |
| Support 1: | 6.91 |
| Support 2: | 6.32 |
| 52w High: | 2.67 |
| 52w Low: | 2.6 |
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.
| EPS | -0.670 |
| Book Value | 12.010 |
| PEG Ratio | 0.00 |
| Gross Profit | 2.697 |
| Profit Margin (%) | -14.80 |
| Operating Margin (%) | 13.24 |
| Return on Assets (ttm) | 1.2 |
| Return on Equity (ttm) | -5.4 |
Wed, 25 Mar 2026
Psychemedics Corp stock faces uncertainty amid quiet trading and shifting drug testing landscape as - AD HOC NEWS
Thu, 05 Dec 2024
Insider Purchase: Director at $PMD (PMD) Buys 1,409,712 Shares - Moomoo
Fri, 21 Jun 2024
After Moving HQ to Dallas, Psychemedics Releases Report on Drug Trends in the U.S. Workplace - Dallas Innovates
Tue, 02 Jan 2024
Small cap drug testing company relocates HQ to DFW from Massachusetts - The Business Journals
Wed, 12 Jul 2023
Psychemedics Corporation Announces CEO Succession Plan - citybiz
Thu, 09 Jun 2022
Psychemedics Nominates Peter Kamin and Darius Nevin to Serve as Members of its Board - citybiz
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |